CEO Paul Hudson talks about latest Sanofi headlines at the Financial Times' Global Pharma and Biotech Summit on Nov. 8. (Credit: Reynald Castañeda for Endpoints News)

Sanofi CEO re­it­er­ates R&D bet is best long-term ap­proach, ad­dress­es probe on mar­ket ma­nip­u­la­tion al­le­ga­tions

Al­though Sanofi CEO Paul Hud­son was at the Fi­nan­cial Times’ Glob­al Phar­ma and Biotech Sum­mit to talk about AI, there was no avoid­ing the ques­tions about its re­cent move to spin out its con­sumer unit as well as the in­ves­ti­ga­tion in France over al­leged mis­lead­ing fi­nan­cial com­mu­ni­ca­tions.

Hud­son re­it­er­at­ed that the con­sumer unit spin­out was all about Sanofi in­vest­ing in the sci­ence. But this was at the cost of aban­don­ing its earn­ings guid­ance for 2025.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.